The FDA's 2026 Crackdown on Compounded GLP-1s: What It Means If You're on One

Written by the GLP-1 Coach editorial team. Last updated September 12, 2026.

If you're on a compounded semaglutide or tirzepatide product, you've probably noticed the headlines piling up over the past year — warning letters, a patent lawsuit, a proposed rule that sounds like it might end compounding altogether. It's a lot, and most coverage of it swings toward one of two poles: compounding is a lifeline, or compounding is a scandal.

We're not going to argue either side. GLP-1 Coach supports logging compounded semaglutide and compounded tirzepatide as medication options because that's what a meaningful share of people actually use, and where you source your medication is a decision between you, your prescriber, and (right now, especially) the regulatory environment — not something we have a stance on. What follows is a timeline of what's actually happened, sourced to FDA announcements and court/company filings rather than secondary coverage, and a practical section on what it means if you're currently on one of these products.

Timeline: how we got here

September 9–16, 2025 — FDA sends 50+ warning letters over marketing, not the drugs themselves. The FDA issued more than 50 warning letters to compounders and telehealth sellers of compounded semaglutide and tirzepatide, the letters dated September 9 and publicly released September 16. The core violation wasn't compounding itself — it was language. The FDA objected to sellers claiming their compounded products were "generic" versions of Ozempic, Wegovy, Mounjaro, or Zepbound, or that they had "the same active ingredient" with equivalent safety and effectiveness. Compounded drugs are not FDA-reviewed for safety or effectiveness before they reach the market, which is what makes an equivalence claim false regardless of what's actually in the vial.

February 6, 2026 — FDA announces intent to restrict the supply of GLP-1 ingredients for compounding. The FDA said it intended to take steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs "mass-marketed" as alternatives to approved medications, naming Hims & Hers directly alongside other compounding pharmacies. The stated goal was to address products the agency "cannot verify" for quality, safety, or efficacy — a step beyond the September letters, which had focused on advertising language rather than access to the ingredients themselves.

February 9, 2026 — Novo Nordisk sues Hims & Hers for patent infringement. Days after the FDA's statement, Novo Nordisk filed suit against Hims & Hers in the U.S. District Court for the District of Delaware, alleging that Hims & Hers' compounded oral semaglutide product infringed U.S. Patent No. 8,129,343 — a patent covering the semaglutide compound itself, not expiring until December 2031. Novo sought a permanent injunction and damages, including enhanced damages for alleged willful infringement.

March 3, 2026 — FDA sends 30 more warning letters. A second wave targeted telehealth companies specifically, for the same category of problem as September: implying their compounded products were equivalent to FDA-approved drugs, and in several cases branding the product with the telehealth company's own name or trademark in a way that obscured which pharmacy was actually doing the compounding.

March 9, 2026 — Novo Nordisk and Hims & Hers settle. This is a fact worth sitting with, because it complicates a simple "crackdown" narrative: Novo Nordisk dismissed its patent lawsuit (without prejudice, reserving the right to refile), and the two companies struck a distribution deal instead. Hims & Hers agreed to carry Novo Nordisk's FDA-approved Ozempic and Wegovy (both injectable and oral forms) on its platform, stop advertising compounded GLP-1 products except on a limited, clinically-necessary basis, and help existing compounded-product patients transition to FDA-approved alternatives "when determined clinically appropriate by their providers." The litigation resolved through a commercial deal, not a court ruling on the merits.

April 1, 2026 — FDA clarifies 503A vs. 503B compounding rules as supply stabilizes. With semaglutide and tirzepatide off the national shortage list, the FDA reiterated the rules that govern the two compounding pathways going forward (details below) and noted that neither drug currently sits on the 503B bulks list or the drug shortage list — the two conditions that let outsourcing facilities compound from bulk substances.

April 30–May 1, 2026 — FDA proposes permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This is the most consequential step so far. Rather than treating the shortage-era exception as temporarily lapsed, the FDA proposed a formal rule finding "no clinical need" for outsourcing facilities to compound these three drugs from bulk substances — a determination that, if finalized, would close the 503B bulk-compounding pathway even if a future shortage occurred. The proposal was published in the Federal Register on May 1, 2026, opening a 60-day public comment period.

June 26, 2026 — comment period extended to July 30, 2026. The FDA granted a 60-day extension after receiving requests that the original window didn't allow enough time for a thoughtful response. As of this writing, the comment period has closed and the FDA has not yet issued a final determination.

FDA's own safety data. Separately from the enforcement timeline, the FDA maintains a running count of adverse events it has received involving compounded GLP-1 products. As of its most recent update (May 31, 2026), the agency reported 990 adverse event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide, including "multiple reports of adverse events, some requiring hospitalization," which the agency ties to dosing errors — both patients self-administering incorrect doses from multidose vials and, in some cases, prescribers miscalculating doses. The FDA also notes this is likely an undercount, since state-licensed 503A pharmacies aren't required to report adverse events to the FDA the way outsourcing facilities are.

We looked for a distinct enforcement action from August 2026 specifically and didn't find one we could verify against a primary source as of this writing — if a further step is announced, we'll update this timeline.

What this actually means if you're on a compounded GLP-1

None of the above is a reason to panic, and it's not our place to tell you what to do with your own prescription — that's a conversation for you and your prescriber. But a few things are worth understanding so you can ask the right questions.

503A vs. 503B: know which one you're on

This distinction is the whole ballgame, and it's the one thing almost every article on this topic glosses over:

• 503A covers compounding by a state-licensed pharmacy (or physician) for a specific, named patient, based on an individual prescription — typically because the FDA-approved product doesn't work for that patient for a documented reason (an allergy to an inactive ingredient, a needed dose or form the manufacturer doesn't make, etc.). It's not meant to operate as a mass-market substitute, and the FDA can act against a 503A pharmacy that's effectively mass-producing "essentially copies" of a commercially available drug.
• 503B covers outsourcing facilities that compound in larger batches, without a patient-specific prescription, generally to fill legitimate supply gaps — this is the pathway that's typically wired up behind the "compounded Ozempic" ads you've seen from telehealth platforms, and it's the pathway the FDA's proposed rule would close for semaglutide, tirzepatide, and liraglutide.

If your product comes through a 503A arrangement tied to a specific, documented reason, the 503B proposal doesn't directly touch you. If it comes through a 503B outsourcing facility — which is common with telehealth-brand compounded products — the regulatory ground under it is shifting, and a final exclusion would end that supply line regardless of future shortages.

The dosing-error risk is real, and it's specific

The FDA's adverse-event data above isn't a vague safety warning — it's tied to a specific mechanism: multidose vials that require you to draw your own dose, versus the pre-filled pens or fixed-dose tablets used for the FDA-approved products. If you're using an injectable compounded product from a multidose vial, confirm you understand exactly how much volume corresponds to your prescribed dose, and don't estimate. See our medical disclaimer for when a symptom warrants urgent care rather than a wait-and-see approach — and if something feels off after a dose, that's a "call your prescriber or go get checked" situation, not a "look it up online" one.

What to actually ask

Two questions, concretely:

1. Is my product 503A or 503B? Your pharmacy should be able to answer this directly and should be able to tell you their state license status.
2. What's the contingency plan if the 503B pathway closes? If you're on a 503B product, ask what happens to your prescription if the proposed exclusion is finalized — whether that's a transition to an FDA-approved product, a different compounding arrangement, or something else. Better to know now than to find out when a refill doesn't go through.

If you're weighing whether to switch products entirely — for cost, supply, or clinical reasons — our guide on switching from semaglutide to tirzepatide covers the practical and clinical side of that transition, independent of which pathway either product came through.

This article is informational, not a recommendation to start, stop, or switch anything. Any decision about your specific medication belongs with your prescriber, who has the full picture of your health history and your product's actual source.

Sources: FDA warning letter example, GLP-1 Solution — 09/09/2025; FDA: FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs, February 6, 2026; Novo Nordisk company statement on Hims & Hers litigation, February 9, 2026; FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s, March 3, 2026; Hims & Hers press release re: Novo Nordisk agreement, March 9, 2026 (SEC EDGAR exhibit); FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize, April 1, 2026; FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, April 30, 2026; Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B, May 1, 2026; Federal Register: Extension of Comment Period, June 26, 2026; FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (adverse event data).